|
Orthologous residues
|
|
p21Cip1 (human): T145‑p, p21Cip1 (mouse): T140‑p, p21Cip1 (dog): T113‑p
|
|
Characterization
|
|
Methods used to characterize site in vivo:
2D analysis, [32P] bio-synthetic labeling, mutation of modification site, peptide sequencing, phospho-antibody
|
|
Relevant cell lines - cell types - tissues:
293T (epithelial), 3T3 (fibroblast) [SHP-2 (mouse), homozygous knockout], MDA-MB453 (breast cell), MEF (fibroblast) [IGF1R (mouse)]
|
|
Cellular systems studied:
cell lines
|
|
Species studied:
human, mouse
|
|
Upstream Regulation
|
|
Potential in vivo enzymes for site:
|
|
Type
|
Enzyme
|
Evidence
|
Notes
|
|
KINASE
|
Akt1 (human)
|
genetic transfer of constitutively active upstream enzyme, genetic transfer of dominant-negative enzyme, pharmacological activator of upstream enzyme, pharmacological inhibitor of upstream enzyme, co-immunoprecipitation
|
|
|
|
Treatments, proteins and their effect on site modification:
|
|
Treatments
|
Referenced Treatments
|
Manipulated Protein
|
Referenced Protein
|
Effect
|
Notes
|
|
insulin
|
|
|
|
increase
|
|
|
LY294002
|
|
|
|
decrease
|
|
|
|
Downstream Regulation
|
|
Effect of modification (function):
intracellular localization
|
|
Comments:
Phosphorylation at T145 of p21Cip1 results in cytoplasmic localization of this protein and regulates its growth-inhibiting activity
|
